Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Solid Tumors and Hematologic Malignancy Clinical Trial

Official title:
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB007839 Following Multiple Oral Doses in Patients With Solid Tumors

Status Completed

Clinical Trial Summary

To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Solid Tumors and Hematologic Malignancy

Clinical Trial Details

NCT number	NCT00820560
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Completed
Phase	Phase 1
Start date	January 2005
Completion date	January 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02492789` - A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients	Phase 1
Terminated	`NCT02712905` - An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies	Phase 1/Phase 2
Completed	`NCT01195311` - A Dose-escalation Study in Subjects With Advanced Malignancies	Phase 1
Withdrawn	`NCT02355431` - Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations	Phase 2
Terminated	`NCT02431260` - An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies	Phase 1/Phase 2